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before the addition of G418 (250 g/ml). Forty-eight hours after electroporation the cells were selected with gancyclovir (2.5 M) for 8 to 10 days. The embryonic stem cell colonies were expanded and screened for homologous recombination by PCR and Southern blotting. Two positive clones were injected into C57BL/6N blastocysts. Five chimeric male and two chimeric female mice with >70% agouti coat color were fertile. Two chimeric males were capable of germline transmission of the ACAT2 fl oxed allele. These mice were originally bred to homozygosity, but the fl oxed allele with NEO cassette intact was severely hypomorphic (<10% normal hepatic ACAT activity), necessitating removal of the NEO cassette. To accomplish this, we bred ACAT2 fl oxed mice with transgenic mice expressing FLP1 recombinase [129S4-Gt(ROSA)26Sortm1(FLP1)Dym/RainJ] maintained on a 129S/ SvJae background (Jackson Laboratory, Bar Harbor, ME). Once FLP1-mediated excision of the NEO cassette was confi rmed by PCR, the FLP1 transgene was bred out of resulting ACAT2 fl oxed mice. When the FLP1 recombined allele was bred to homozygosity, it was confi rmed that the hypomorphic allele had been rescued, given that ACAT2 protein and ACAT2 enzymatic activity was not signifi cantly different from that of ACAT2 wild-type mice (data not shown). To generate intestine-specifi c and liver-specifi c ACAT2 knockout, mice with two ACAT2 fl oxed alleles were bred to mice transgenically expressing Cre recombinase under the villin promoter (B6.SJL-Tg(Vil-cre)997Gum/J) or albumin promoter (B6. Cg-Tg(Alb-cre)21Mgn/J), respectively. The Cre trangenics were purchased from Jackson Laboratory (Bar Harbor, ME). Genotyping was confi rmed by PCR of genomic DNA using primers fl anking the loxP site in intron 13-14 using the following primers (forward: 
Dietary studies
Only female mice were included in the study having been bred on a mixed background as described above. At the age of 7 to 12 weeks, subgroups of mice were fed with a semisynthetic diet containing 20% of energy as lard and added cholesterol at levels of 0.05, 0.1, or 0.5% (wt/wt) for a total of 6 weeks. Blood was drawn at baseline, 3 weeks, and 6 weeks. Necropsies were performed in mice fasted from 9:00 AM until 1:00 PM as previously described (3) (4) (5) (6) (7) 14 ) . All mice used in the studies were housed in a pathogen-free barrier facility at Wake Forest University School of Medicine with the approval of the American Association for Accreditation of Laboratory Animal Care. The Institutional Animal Care and Use Committee approved all protocols before execution of the studies.
Plasma lipid and lipoprotein analysis
Total plasma cholesterol (TPC) and TG concentrations were measured using colorimetric assay as previously described (3) (4) (5) (6) (7) 14 ) . Cholesterol distribution was quantifi ed by FPLC as previously described (3) (4) (5) (6) (7) 14 ) .
Immunoblotting
Microsomal proteins (25 g/lane of liver and 15 g/lane of intestine) were separated by 4 to 12% SDS-PAGE Tris-glycine gel, transferred to nitrocellulose membranes, and incubated with anti-ACAT2 rabbit polyclonal ( 19 ) or anti-BiP rabbit polyclonal antibodies (Stressgen Biotechnologies Corp., Canada) as described previously (3) (4) (5) (6) (7) 14 ) . reduced plasma total cholesterol and VLDL-cholesterol, decreased plasma CE, and increased plasma triglyceride (TG) concentration. These studies indicate that the lack of hepatic cholesterol esterifi cation and the reduced CE secretion into VLDL, as also observed in total body ACAT2 Ϫ / Ϫ mice, is atheroprotective.
Intestinal ACAT2 determines how much cholesterol gets packaged into chylomicrons as CE and transported in lymph and plasma ( 8 ) . Isotopic tracer measurements revealed that the cholesterol absorption rates varied from 20% to 80% of total cholesterol (around 1,500 mg/day in humans) present in the lumen ( 9 ) . The majority of cholesterol delivered to the liver is esterifi ed and resides in the core of chylomicron remnants. Nonspecifi c ACAT inhibitors have been shown to decrease cholesterol absorption by 20 to 80% in rats, hamsters, rabbits, pigs, and nonhuman primates (10) (11) (12) (13) (14) . Whole body ACAT2 Ϫ / Ϫ mice also have a 40% to 85% reduced level of cholesterol absorption ( 8, (15) (16) (17) (18) . Collectively, this implies that cholesterol esterifi cation by intestinal ACAT2 plays an important role in regulating cholesterol sequestration for transport into the body.
Although the blunted cholesterol absorption via intestinal ACAT2 inhibition is anticipated to be hypocholesterolemic, the specifi c contribution made by intestine-derived CE to whole body cholesterol homeostasis is still unclear. A nonselective deletion or inhibition of ACAT2 would be expected to render the maximal cholesterol-lowering effect as described above and is apparently due to a combined inhibitory effect on hepatic and intestinal ACAT2 activities. To design effective therapeutic strategies targeting ACAT2-driven cholesterol esterifi cation, we believe it is critically important to understand the function of ACAT2 in the small intestine and liver. This prompted us to create tissue-specifi c ACAT2 knockout (KO) mouse models. The hypothesis tested herein is whether blocking the infl ux of cholesterol only from intestine, as expected from intestinespecifi c ACAT2 KO mice, would protect animals from hypercholesterolemia and tissue cholesterol accumulation to a similar extent as seen in liver-specifi c ACAT2 KO mice.
MATERIALS AND METHODS

Generation of ACAT2 fl oxed mice
Conditional targeting of the mouse ACAT2 gene was achieved as depicted in Fig. 1A . An ACAT2 targeting vector was constructed to introduce loxP sites upstream and downstream of exons 11 to 13, which contain active site residues necessary for enzyme catalysis. To generate this targeting vector, regions of homology were generated by PCR using genomic DNA from mouse liver (129S6/ SvEv strain) as a template. Both the short and long arm of homology were then inserted into the targeting vector pJB1 (kindly provided by Joachim Herz, University of Texas Southwestern Medical Center), which contained the NEO gene driven by the murine phosphoglycerate kinase promoter, fl anked by loxP and FRT sites, and followed by two copies of the herpes simplex virus thymidine kinase genes. This vector also contains FRT sites fl anking the neomycin resistance gene, which facilitates removal of the NEO cassette by Flp recombinase. This construct was linearized by digestion with Pme I and electroporated into SvEv mouse-derived embryonic stem cells. The cells were seeded onto STO feeder layers for 24 
Quantitative real-time PCR
Tissue RNA extraction and quantitative PCR was conducted as previously described (3) (4) (5) (6) (7) 14 ) using the applied biosystems 7500 Real-Time PCR System. Primer sequences used for quantitative PCR are available on request.
Statistical analyses
All graphs were plotted by GraphPad Prism 5.05. Data were analyzed by ANOVA with Tukey post hoc test. Statistically significant differences were considered at P < 0.05.
RESULTS
Conditional targeting of the ACAT2 allele allows for tissue-specifi c deletion
Initial studies indicated that homozygous fl oxed mice (ACAT2 fl /fl ) that had been crossed with FLP-1 expressing mice had similar ACAT2 protein and activity as wild-type mice (ACAT2 WT/WT ; data not shown). For tissuespecifi c ACAT2 knockouts, intercrosses of heterozygotes (ACAT2 WT/fl ) yielded the expected 25% homozygotes. Both the ACAT2 L Ϫ /L Ϫ and ACAT2 SI Ϫ /SI Ϫ mice developed normally, were fertile, and exhibited normal body weight
Microsomal ACAT activity assay
ACAT activity was quantifi ed by methods previously published ( 20, 21 ) . Briefl y, an aliquot of liver and small intestine segment 2 were homogenized in ACAT homogenization buffer in the presence of protease inhibitor cocktail. The microsomes were isolated, and the ACAT assays were performed in the absence and presence of 0.1 mM pyripyropene A, an ACAT2-specifi c inhibitor, so that ACAT1 and ACAT2 activities could be calculated from total ACAT activity. Relative ACAT enzyme activity was expressed as nmol CE synthesized per mg microsomal protein per min (nmol/mg/min).
Cholesterol absorption measurement by fecal dualisotope
During the fourth week of diet treatment, all mice were gavaged with 50 l soybean oil containing [ 14 C]cholesterol and ␤ -[ 3 H]sitosterol. Fractional cholesterol absorption and fecal neutral sterol loss were quantifi ed using previously published methods ( 6, 14 ) .
Hepatic, intestinal, and biliary lipid analysis
Extraction of biliary, intestinal, and liver lipids for enzymatic quantifi cation of total triglyceride, cholesteryl esters, FC, phospholipids, and bile acids were performed as previously described (3) (4) (5) (6) (7) 14 ) . During necropsy, small intestine was fl ushed thoroughly with saline. The entire intestine was folded and cut into four equal length segments. Only segment 2 was used for cholesterol assay. ACAT2 L ؊ /L ؊ and ACAT2 SI ؊ /SI ؊ mice have higher plasma concentrations of TG and lower concentrations of VLDL-C After consuming the experimental diets for 6 weeks, ACAT2 L Ϫ /L Ϫ mice had signifi cantly higher concentrations of plasma TG at any given dietary cholesterol level compared with ACAT2 fl /fl mice ( Fig. 3A ). An increased level of plasma TG also was observed in ACAT2 SI Ϫ /SI Ϫ mice when fed with 0.05% and 0.5% (wt/wt) cholesterol diet ( Fig. 3A ) . ACAT2 L Ϫ /L Ϫ mice had a lower level of TPC on 0.05% cholesterol diet ( Fig. 3B ) . The difference was presumably due to the reduction of LDL-C when compared with the response in ACAT2 fl /fl mice ( Fig. 3C ) . TPC was not different among three genotypes of mice when the mice were fed the 0.1% cholesterol diet ( Fig. 3B ). After being fed the 0.5% cholesterol diet for 6 weeks, conditional KO mice had decreased levels of TPC compared with control mice ( Fig. 3B ). Cholesterol distribution by FPLC indicated that VLDL-C was signifi cantly reduced among ACAT2 L Ϫ /L Ϫ and ACAT2 SI Ϫ /SI Ϫ mice after consuming 0.1% and 0.5% cholesterol diet for 6 weeks ( Fig. 3D ). There was no effect of diet or genotype on HDL cholesterol levels ( Fig. 3E ).
ACAT2 L ؊ /L ؊ and ACAT2 SI ؊ /SI ؊ mice are protected from diet-induced hepatic cholesterol accumulation
Liver weight and body weight were not different among experimental animals at the time of necropsy ( Fig. 4A ). ACAT2 fl /fl mice had a stepwise increase of hepatic total cholesterol (TC) ( Fig. 4B ) and CE ( Fig. 4C ) in response to increased dietary cholesterol. In contrast, ACAT2 L Ϫ /L Ϫ and ACAT2 SI Ϫ /SI Ϫ mice had only modest levels of TC and CE at any given dietary cholesterol level ( Fig. 4B, C ) . Interestingly, hepatic TC and CE levels were reduced to strikingly similar concentrations in ACAT2 L Ϫ /L Ϫ and ACAT2 SI Ϫ /SI Ϫ mice regardless of dietary cholesterol levels. Hepatic free cholesterol (FC) was not different among three genotypes when fed with 0.05% and 0.1% dietary cholesterol ( Fig. 4D ). However, ACAT2 L Ϫ /L Ϫ and ACAT2 SI Ϫ /SI Ϫ mice had significantly lower levels of FC in the liver on the 0.5% cholesterol diet, although it was the same as in other dietary groups ( Fig. 4D ). The average for hepatic TG was slightly lower in both groups of KO mice fed 0.1% dietary cholesterol compared with the level of TG in the ACAT2 fl /fl mice. The TG concentration differences were statistically significant when ACAT2 L Ϫ /L Ϫ and ACAT2 SI Ϫ /SI Ϫ mice consumed 0.5% dietary cholesterol ( Fig. 4E ). Phospholipid concentrations were not signifi cantly different at any level of dietary cholesterol feeding for any of the genotypes ( Fig. 4F ).
ACAT2 SI ؊ /SI ؊ mice have less cholesteryl ester accumulation in the small intestine
After dietary cholesterol intake, all the experimental mice had similar intestine weights, represented by segment 2 in Fig. 5A . ACAT2 SI Ϫ /SI Ϫ mice appeared to have slightly increased levels of TC in the intestine in response to increasing levels of dietary cholesterol ( Fig. 5B ) , although only the intestine of ACAT2 SI Ϫ /SI Ϫ mice had signifi cantly higher concentrations of TC after 6 weeks when fed rodent chow or a cholesterol-enriched diet. ACAT2 protein in ACAT2 L Ϫ /L Ϫ mice was undetectable in the liver but was expressed at normal levels in the intestine compared with the ACAT2 fl /fl mice (Fig. 1B) . Hepatic ACAT2 activity was reduced by 99.7% in ACAT2 L Ϫ /L Ϫ mice compared with ACAT2 fl /fl mice ( Fig. 1C ). As anticipated, this pattern was opposite in ACAT2 SI Ϫ /SI Ϫ mice, where ACAT2 protein was not detected in the small intestine, whereas hepatic ACAT2 was unaltered in ACAT2 SI Ϫ /SI Ϫ mice ( Fig. 1B ) . Intestinal ACAT2 activity was decreased by 95.6% compared with ACAT2 fl /fl mice ( Fig. 1C ).
ACAT2
SI ؊ /SI ؊ mice, but Not ACAT2 L ؊ /L ؊ Mice, have diminished cholesterol absorption ACAT2 fl /fl mice had a stepwise decrease of percentage cholesterol absorption in response to increased dietary cholesterol ( Fig. 2A ). ACAT2 L Ϫ /L Ϫ mice did not have signifi cantly different percentage absorption values compared with control mice at any dietary cholesterol level ( Fig. 2A ) . However, signifi cantly decreased levels of cholesterol absorption were observed in ACAT2 SI Ϫ /SI Ϫ mice for each different dietary cholesterol level when compared with control and ACAT2 L Ϫ /L Ϫ mice ( Fig. 2A ). ACAT2 fl /fl mice had a stepwise increase in fecal sterol loss that occurred to similar levels as that of ACAT2 L Ϫ /L Ϫ mice ( Fig. 2B ). ACAT2 SI Ϫ /SI Ϫ mice had signifi cantly more fecal sterol loss at 0.05% and 0.1% dietary cholesterol levels, but values were comparable at the 0.5% cholesterol level when compared with ACAT2 fl /fl control mice ( Fig. 2B ). 
DISCUSSION
Previous ACAT2 ASO studies ( 5-7 ) have demonstrated that hepatic ACAT2 plays a central role in controlling whole body cholesterol homeostasis. This perspective is based on the fact that hepatic ACAT2 was knocked down by over 90% by ASO treatment, whereas intestinal ACAT2 generally remained intact among those ACAT2 ASO studies. However, low remaining levels of hepatic ACAT2 activity in the ASO studies made interpretation less than defi nitive. Through LoxP-Cre recombinase technologies, we have successfully generated two novel ACAT2 conditional KO models, the liver-specifi c (ACAT2 L Ϫ /L Ϫ ) and the intestine-specifi c (ACAT2 SI Ϫ /SI Ϫ ) KO mice. The reductions in tissue and plasma cholesterol and lipoprotein concentrations of ACAT2 L Ϫ /L Ϫ mice as shown here generally agree with results from previous studies using mice with whole body ACAT2 KO or ASO-mediated ACAT2 knockdown ( 4-7, 15, 16 ) . The consequences of increased dietary cholesterol in hepatic and plasma lipid changes of ACAT2 SI Ϫ /SI Ϫ mice were essentially the same as occurred in ACAT2 L Ϫ /L Ϫ mice and were minimal when compared with those of ACAT2 intact mice. The cholesterol changes (higher of consumption of 0.5% dietary cholesterol compared with that of control mice ( Fig. 5B ). When the mice had no intestinal ACAT2, CE concentrations of intestine were signifi cantly lower at all levels of dietary cholesterol intake compared with control and ACAT2 L Ϫ /L Ϫ mice ( Fig. 5C ). Intestinal FC was signifi cantly increased in ACAT2 SI Ϫ /SI Ϫ mice fed 0.5% dietary cholesterol ( Fig. 5D ). However, no difference in FC was observed among animals of either genotype fed diets with 0.05% or 0.1% cholesterol.
ACAT2 SI ؊ /SI ؊ but not ACAT2 L ؊ /L ؊ mice have lower levels of biliary cholesterol
In response to cholesterol feeding, ACAT2 fl /fl mice tend to have a small increase of biliary cholesterol, although the dietary effect was not statistically signifi cant ( Fig. 6A ). ACAT2 L Ϫ /L Ϫ mice had similar level of biliary cholesterol compared with control mice ( Fig. 6A ) . In contrast, ACAT2 SI Ϫ /SI Ϫ mice had signifi cantly lower levels of biliary cholesterol with no evidence of a response to increasing dietary cholesterol compared with ACAT2 fl/fl and ACAT2 L Ϫ /L Ϫ mice. There was no dietary or genotype difference in biliary phospholipids and total bile acid among the animals ( Fig. 6B, C ) . in the intestine alone is suffi cient to alleviate most of the dietary cholesterol burden in the circulation and tissues. We have previously shown that, in the absence of ACAT2 in the intestine, the effi ciency of absorption and TC and FC but lower CE) of enterocytes of intestine among ACAT2 SI Ϫ /SI Ϫ mice were consistent with the reports from Turley and colleagues ( 18 ) . The present data suggest that blocking cholesterol esterifi cation and absorption the perfusate when ACAT2 was unable to provide CE ( 6, 7 ) . These data led to the speculation that the higher availability of TG for secretion resulted from a higher rate of mobilization of hepatic TG ( 7 ) . A suggestion was made that the lack of CE in the intracellular lipid droplets could have led to a more rapid fatty acid mobilization of preformed TG via intracellular triglyceride hydrolases, although the identity of the hydrolytic enzymes involved is unknown ( 7 ) . ACAT2 SI Ϫ /SI Ϫ mice also appeared to have higher plasma TG in response to increased amounts of dietary cholesterol. The exact mechanism is unknown. From lymph duct cannulation studies in our laboratory, chylomicrons from ACAT2
Ϫ / Ϫ mice have more TG mass compared with wildtype mice ( 8 ) . However, due to rapid and effi cient clearance of chylomicron remnants from the circulation by liver ( 22, 23 ) , this would not appear to be a major mechanism of TG increase in the plasma. It is possible that, as a result of chylomicrons delivering less CE to the liver in ACAT2 SI Ϫ /SI Ϫ mice, a CE-poor lipid droplet may result in the liver, leading to a similar effect on TG mobilization as was observed in mice with the loss of hepatic ACAT2 ( 6, 7 ) . An interesting phenotype in the ACAT2 conditional KO mice is that free cholesterol (FC) does not accumulate in the liver in response to dietary cholesterol feeding. Especially among the ACAT2 L Ϫ /L Ϫ mice, a large quantity of dietary FC is delivered to the liver, but it cannot be esterifi ed. Logically one would anticipate that hepatic FC would be elevated. However, hepatic FC was not increased after dietary cholesterol feeding ( Fig. 4D ). Furthermore, no difference in FC level was detected in feces ( Fig. 2B ) , bile ( Fig. 6A ), or total plasma cholesterol ( Fig. 3B ). Among previous studies in mice with hepatocyte-specifi c knockdown of ACAT2 using ASOs, we found that more FC appeared in the liver perfusate, whereas CE secretion persisted ( 6 ) . In those studies we demonstrated that excessive hepatic FC was delivered to the proximal small intestine for fecal disposal. In pilot liver perfusion studies, we found that FC was not different between ACAT2 L Ϫ /L Ϫ and ACAT2 fl /fl control mice (J.M. Brown, J.K. Sawyer, M.A. Davis, and L.L. Rudel, unpublished observations). One major difference between the current studies and the work by Brown et al. ( 6 ) is that the latter was done in the mice on LDLr Ϫ / Ϫ apoB-100 only background. The absence of the LDL receptor dramatically alters hepatic lipoprotein metabolism. Additional studies are needed to clarify the mechanism by which excessive free cholesterol accumulation is avoided in ACAT2 L Ϫ /L Ϫ mice fed high levels of dietary cholesterol.
Another possible mechanism of cholesterol traffi cking out of the liver is through the membrane receptordependent pathway. Of particular interest is that ABCA1 is signifi cantly increased in ACAT2 L Ϫ /L Ϫ animals (Supplementary Table I ). ABCA1 functions as a membrane transporter exporting free cholesterol out of the tissues and cells. Our group previously showed that ABCA1 was upregulated in the liver when hepatic ACAT2 was specifi cally knocked down by ASO ( 6 ) . Data presented herein suggested that ABCA1 mRNA expression tended to increase. transport of cholesterol in chylomicrons is greatly reduced because cholesterol esters cannot be formed for transport into the body in chylomicrons ( 8 ) . Even though some unesterifi ed cholesterol can be transported in chylomicrons in the absence of intestinal ACAT2 ( 8 ), the present data suggest it is not suffi cient to stimulate the hepatic and plasma lipoprotein responses to dietary cholesterol that are typical in ACAT2 suffi cient mice. The present study extends our current understanding of the important role of intestinal-derived CE in cholesterol traffi cking in vivo.
In addition to the expected decreases in plasma VLDL-C seen in ACAT2 defi ciency, one of the characteristic changes in plasma lipids was the signifi cant increase of TG in the conditional ACAT2 knockouts, especially in ACAT2 L Ϫ /L Ϫ mice. Similar fi ndings were observed in several other studies using whole body ACAT2 KO or ASOmediated hepatic ACAT2 knockdown models ( 4-7, 15, 16 ) . Liver perfusion assay indicated that more TG appeared in However, plasma HDL was not signifi cantly elevated, which would have been expected with increased levels of hepatic ABCA1. Future experiments with hepatocytespecifi c deletion of ABCA1 and ACAT2 will allow us to address whether ABCA1 is necessary for export of hepatic cholesterol when ACAT2 is absent.
Our group recently showed in mice that cholesterol absorption and transport in chylomicrons as CE is significantly decreased due to the loss of intestinal ACAT2 ( 8 ) .
In the absence of ACAT2, chylomicrons collected via thoracic lymph duct cannulation were depleted in core CE, which had been replaced mainly with TG without any particle size alteration ( 8 ) . When these CE-poor chylomicrons are delivered to liver as remnants, it presumably results in less cholesterol accumulation in the liver and subsequently less VLDL-C circulated into the blood. This implies possible pharmaceutical strategies for targeting intestinal ACAT2 to achieve a hypocholesterolemic effect. Furthermore, when probing for ACAT2 proteins from human liver and intestine biopsy samples, we have found that in many cases hepatic ACAT2 is expressed at a vanishingly low level, which is in contrast to the high expression level of ACAT2 in the human intestine (M.A. Davis and L.L. Rudel, unpublished observations). This also highlights what could be a potential approach to treat hypercholesterolemia in humans. Developing novel ACAT2 inhibitors could also benefi t patients of lysosomal lipid storage diseases, such as lysozomal acid lipase defi ciency or Niemann-Pick C diseases, where there is massive accumulation of cholesteryl esters or a build-up of unesterifi ed cholesterol in a variety of tissues especially the liver (24) (25) (26) . Another approach to lower intestinal cholesterol absorption is to inhibit the apical membrane transporter, the Niemann-Pick C1-like 1 (NPC1L1) protein, of the intestine. Ezetimibe, prescribed in clinics as Zetia, can effectively lower plasma LDL-C (27) (28) (29) , presumably through its ability to inhibit NPC1L1 in enterocytes, which likely occurs without any defect in cholesterol esterifi cation. Despite the reduced cholesterol absorption in both scenarios, the underlying mechanism would be distinctly different. This may warrant future studies to investigate whether there are advantages of developing intestinal ACAT2 inhibitors for reduction of CE transport during atherosclerosis progression versus the alternative approach of blocking cholesterol uptake from the intestinal lumen via NPC1L1.
In conclusion, our data demonstrate for the fi rst time that CEs derived from liver and intestine promote potentially atherogenic hepatic CE accumulation and hyperlipidemia. Hepatic and intestinal ACAT2 could be potential pharmaceutical targets to prevent hypercholesterolemia and atherosclerosis progression. The present results suggest that inhibition of intestinal or hepatic ACAT2 can improve atherogenic hyperlipidemia, indicating that tissue-specifi c inhibitors for ACAT2 could be benefi cial for atheroprotection.
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